Sensus Healthcare Q2 Earnings Call Highlights

Impact · against what's priced in

SRTS faces significant short-term headwinds due to a steep revenue decline and widening losses, though a timing-related recovery in Q3 provides a modest offset. The long-term outlook is clouded by the loss of a major customer's purchasing power and a shrinking cash runway.

SRTS−0.30

No priced-in read yet

In context

Revenue plummeted from $7.3 million to $2.3 million year-over-year with net losses widening to $8.7 million, partially offset by the expectation that eight delayed units (approx. $2M value) will be recognized in Q3.

Read from the article alone

• ebitda▲44%
• earnings
• healthcare
• SRTS
• dermatology
• financing delay
• international expansion
• medical devices
• revenue miss